Skip to content

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Jul 17, 2026

Data as of Oct 16

▼ SELL$16.2K324 shares at $49.97Benjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.
Watch ELVN
Traded
Jul 17, 2026
Disclosed
Jul 21, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Jul 17, 2026TRADEDDISCLOSED
ELVNSimilar stocks (XLV — its sector index fund), rebased to ELVN's price on the disclosure day
ELVN since disclosure
−31.3%
after the sale
Similar stocks (XLV) since disclosure
+10.3%
XLV — its sector index fund

Change in closing price from Jul 21, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$19Kdisclosed Jul 21 · filed 4 days after the trade
  2. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$141Kdisclosed Jul 21 · filed 4 days after the trade
  3. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$134Kdisclosed Jul 21 · filed 4 days after the trade
  4. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$6.6Kdisclosed Jul 21 · filed 4 days after the trade

See every trade on ELVN →